- Home
- ANGO vs CTNM Comparison
ANGO vs CTNM Comparison
Compare ANGO & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ANGO | CTNM |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 420.2M | 489.4M |
| IPO Year | 2004 | 2024 |
Fundamental Metrics
Financial Performance| Metric | ANGO | CTNM |
|---|---|---|
| Price | $12.18 | $11.94 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $18.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 276.5K | 158.6K |
| Earning Date | 04-02-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.92 | 0.46 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $291,010,000.00 | N/A |
| Revenue This Year | $9.51 | N/A |
| Revenue Next Year | $4.96 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $8.36 | $3.57 |
| 52 Week High | $13.99 | $16.33 |
Technical Indicators
Market Signals| Indicator | ANGO | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 61.18 | 40.46 |
| Support Level | $10.45 | $11.62 |
| Resistance Level | $12.72 | $13.26 |
| Average True Range (ATR) | 0.39 | 0.75 |
| MACD | 0.06 | -0.19 |
| Stochastic Oscillator | 79.04 | 18.54 |
Price Performance
Historical ComparisonAbout ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.